Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: Results from a large observational cohort study (SCOLTA)

L. Taramasso, P. Tatarelli, E. Ricci, G. Madeddu, B. Menzaghi, N. Squillace, G.V. De Socio, C. Martinelli, R. Gulminetti, P. Maggi, G. Orofino, F. Vichi, A. Di Biagio, P. Bonfanti, C. Bellacosa, L. Calza, C. Abeli, B.M. Celesia, C. Grosso, A. StagnoF. Mazzotta, G. Penco, G. Cassola, L.A. Nicolini, C. Dentone, C. Molteni, L. Palvarini, A. Scalzini, L. Carenzi, G. Rizzardini, L. Valsecchi, L. Cordier, S. Rusconi, V. Colombo, M. Galli, M. Franzetti, A. Sgrelli, E. Mazzotta, G. Parruti, P. Bagella, M.S. Mura, R. Libertone, A. Antinori, S. Di Giambenedetto, M. Guastavigna, P. Caramello

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Article number357
JournalBMC Infectious Diseases
Volume18
Issue number1
DOIs
Publication statusPublished - 2018

Keywords

  • Cholesterol
  • Dyslipidemia
  • Framingham risk score
  • Integrase inhibitors
  • Rilpivirine
  • cholesterol
  • dolutegravir
  • efavirenz
  • elvitegravir
  • high density lipoprotein cholesterol
  • lipid
  • low density lipoprotein cholesterol
  • rilpivirine
  • ritonavir
  • triacylglycerol
  • virus RNA
  • adult
  • antiretroviral therapy
  • Article
  • cholesterol blood level
  • cohort analysis
  • controlled study
  • drug substitution
  • drug withdrawal
  • dyslipidemia
  • female
  • follow up
  • human
  • Human immunodeficiency virus infection
  • lipid analysis
  • major clinical study
  • male
  • observational study
  • prospective study

Cite this